Compare BSRR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | ARVN |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.1M | 516.2M |
| IPO Year | 2001 | 2018 |
| Metric | BSRR | ARVN |
|---|---|---|
| Price | $40.39 | $8.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $37.00 | $15.05 |
| AVG Volume (30 Days) | 58.2K | ★ 535.5K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 10.28 | ★ 58.84 |
| EPS | ★ 1.72 | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $23.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.49 | $6.06 |
| 52 Week High | $43.13 | $14.22 |
| Indicator | BSRR | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 42.81 |
| Support Level | $39.72 | $7.90 |
| Resistance Level | $42.17 | $8.40 |
| Average True Range (ATR) | 1.44 | 0.26 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 47.82 | 13.86 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. It offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.